Matthew Feinsod - Apr 10, 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Role
Chief Medical Officer
Signature
/s/ Andrew Oxtoby, Attorney-in-Fact
Stock symbol
KLRS
Transactions as of
Apr 10, 2025
Transactions value $
$0
Form type
4
Date filed
4/11/2025, 04:52 PM
Previous filing
Mar 18, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KLRS Stock Option (Right to Buy) Award $0 +70.6K $0.00 70.6K Apr 10, 2025 Common Stock 70.6K $7.31 Direct F1
transaction KLRS Stock Option (Right to Buy) Award $0 +101K $0.00 101K Apr 10, 2025 Common Stock 101K $7.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on December 31, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
F2 The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.